HUP0202753A2 - A loteprednol és B2 adrenoreceptor agonisták új kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
A loteprednol és B2 adrenoreceptor agonisták új kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk Download PDFInfo
- Publication number
- HUP0202753A2 HUP0202753A2 HU0202753A HUP0202753A HUP0202753A2 HU P0202753 A2 HUP0202753 A2 HU P0202753A2 HU 0202753 A HU0202753 A HU 0202753A HU P0202753 A HUP0202753 A HU P0202753A HU P0202753 A2 HUP0202753 A2 HU P0202753A2
- Authority
- HU
- Hungary
- Prior art keywords
- loteprednol
- pharmaceutical composition
- composition according
- treatment
- respiratory disorders
- Prior art date
Links
- 229960001798 loteprednol Drugs 0.000 title claims description 37
- 239000000556 agonist Substances 0.000 title description 4
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 claims abstract description 12
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 10
- 229940124225 Adrenoreceptor agonist Drugs 0.000 claims abstract description 5
- 150000002148 esters Chemical class 0.000 claims abstract description 4
- 241000124008 Mammalia Species 0.000 claims abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 8
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims description 47
- 239000003814 drug Substances 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 14
- 229960002848 formoterol Drugs 0.000 claims description 13
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 229960003744 loteprednol etabonate Drugs 0.000 claims description 11
- 206010020751 Hypersensitivity Diseases 0.000 claims description 10
- 230000007815 allergy Effects 0.000 claims description 10
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 7
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 6
- 239000000150 Sympathomimetic Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229960002052 salbutamol Drugs 0.000 claims description 6
- 230000001975 sympathomimetic effect Effects 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 229960004017 salmeterol Drugs 0.000 claims description 5
- 229960002720 reproterol Drugs 0.000 claims description 3
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 229940064707 sympathomimetics Drugs 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 description 19
- 208000006673 asthma Diseases 0.000 description 15
- 229960001334 corticosteroids Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 description 11
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 description 11
- 210000001541 thymus gland Anatomy 0.000 description 10
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 9
- 229960004436 budesonide Drugs 0.000 description 9
- 229960002714 fluticasone Drugs 0.000 description 9
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 206010014950 Eosinophilia Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000013566 allergen Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 210000003979 eosinophil Anatomy 0.000 description 6
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000011287 therapeutic dose Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 3
- 229940092705 beclomethasone Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 238000011685 brown norway rat Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 231100000816 toxic dose Toxicity 0.000 description 3
- 229940121786 Beta 2 adrenoreceptor agonist Drugs 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000007885 bronchoconstriction Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000004410 intraocular pressure Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229940127212 long-acting beta 2 agonist Drugs 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229940127211 short-acting beta 2 agonist Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 description 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
- XSFWDHONRBZVEJ-UHFFFAOYSA-N 7-[3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-1,3-dimethylpurine-2,6-dione;hydron;chloride Chemical compound Cl.C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 XSFWDHONRBZVEJ-UHFFFAOYSA-N 0.000 description 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 1
- 101710152983 Beta-2 adrenergic receptor Proteins 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 101000941450 Lasioglossum laticeps Lasioglossin-1 Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000607662 Salmonella enterica subsp. enterica serovar Abortusequi Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229940119457 Steroid receptor agonist Drugs 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 208000012871 acute dyspnea Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960000193 formoterol fumarate Drugs 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000030500 lower respiratory tract disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229960000261 reproterol hydrochloride Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Abstract
A találmány tárgya olyan gyógyszerkészítmény, amely (i) egy lágyszteroid és/vagy gyógyászatilag tolerálható észterének és (ii)legalább egy b2 adrenoreceptor agonistának a hatékony mennyiségéttartalmazza egyidejű, egymás után vagy külön-külön belégzéssel történőbeadásra légúti rendellenességek emlősökben való kezelésére. Ó
Claims (10)
- Szabadalmi igénypontok1. Gyógyszerkészítmény, amely külön vagy együtt (i) egy lágy szteroid és/vagy gyógyászatiig tolerálható észterének és (ii) legalább egy β2 adrenoreceptor agonistának a hatékony mennyiségét tartalmazza egyidejű, egymás után vagy külön-külön belégzéssel történő beadásra légúti rendellenességek emlősökben történő kezelésében.
- 2. Az 1. igénypont szerinti gyógyszerkészítmény, amelyben a lágy szteroid a loteprednol vagy egy gyógyászatilag tolerálható észtere.
- 3. Az 1. vagy 2. igénypont szerinti gyógyszerkészítmény, amelyben a lágy szteroid a loteprednol-etabonát.
- 4. Az 1-3. igénypontok bármelyike szerinti gyógyszerkészítmény, amelyben a β2 adrenoreceptor agonistát a szalbutamol, reproterol, szalmeterol, formoterol és ezek gyógyászatilag tolerálható sóinak csoportjából választjuk.
- 5. Az 1-4. igénypontok bármelyike szerinti gyógyszerkészítmény, amely (i) loteprednolt és (ii) formoterolt tartalmaz.
- 6. Az 1-4. igénypontok bármelyike szerinti gyógyszerkészítmény, amely (i) loteprednolt és (ii) szalmeterolt tartalmaz.
- 7. Az 1-4. igénypontok bármelyike szerinti gyógyszerkészítmény, amely (i) loteprednolt és (ii) reproterolt tartalmaz.
- 8. Allergiák és/vagy légúti rendellenességek kezelésére szolgáló gyógyszer, amely (i) loteprednol és (ii) legalább egy β2 szimpatomimetikum hatékony mennyiségét tartalmazza meghatározott vagy szabad kombinációban, szükség esetén szokásos kötőanyagokkal vagy vivőanyagokkal együtt.
- 9. Eljárás allergiák és/vagy légúti rendellenességek kezelésére szolgáló gyógyszer előállítására, amely gyógyszer loteprednol hatóanyagot és legalább egy β2 szimpatomimetikumot tartalmaz, azzal jellemezve, hogy a loteprednolt és a β2 szimpatomimetikumot vagy β2 szimpatomimetikumokat külön-külön vagy együtt összekeverjük, szükség esetén szokásos kötőanyagokkal vagy vivőanyagokkal együtt, majd az így kapott keveréket megfelelő beadási formákká alakítjuk.
- 10. A loteprednol és legalább egy β2 szimpatomimetikum keverékének alkalmazása allergiák és/vagy légúti rendellenességek egyidejű, egymás utáni vagy különálló kezelésére szolgáló gyógyszer előállítására.A meghatalmazott:gödölle, kékes, MÉSZÁROS & SZABÓ Szabadalmi és Védjegy Iroda1024 Budapest, Keleti Károly u. 13/b Frankné dr. Machytka Daisy szabadalmi ügyvivő
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19947235A DE19947235A1 (de) | 1999-09-30 | 1999-09-30 | Neue Kombination von Loteprednol und beta¶2¶-Adrenorezeptor-Agonisten |
| PCT/EP2000/009392 WO2001022956A2 (de) | 1999-09-30 | 2000-09-26 | NEUE KOMBINATION VON LOTEPREDNOL UND β2-ADRENOZEPTOR-AGONISTEN |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0202753A2 true HUP0202753A2 (hu) | 2002-12-28 |
| HUP0202753A3 HUP0202753A3 (en) | 2004-06-28 |
Family
ID=7924101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0202753A HUP0202753A3 (en) | 1999-09-30 | 2000-09-26 | Pharmaceutical compositions containing novel combination of loteprednol and b2-adrenoceptor agonists and their use |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7521438B1 (hu) |
| EP (1) | EP1216047B1 (hu) |
| JP (1) | JP5068912B2 (hu) |
| AR (1) | AR025924A1 (hu) |
| AT (1) | ATE306271T1 (hu) |
| AU (1) | AU7907400A (hu) |
| BR (1) | BR0014374B1 (hu) |
| CA (1) | CA2389111C (hu) |
| CY (1) | CY1105548T1 (hu) |
| CZ (1) | CZ296396B6 (hu) |
| DE (2) | DE19947235A1 (hu) |
| DK (1) | DK1216047T3 (hu) |
| EE (1) | EE05050B1 (hu) |
| ES (1) | ES2248131T3 (hu) |
| HU (1) | HUP0202753A3 (hu) |
| MX (1) | MXPA02003329A (hu) |
| PL (1) | PL196729B1 (hu) |
| SI (1) | SI1216047T1 (hu) |
| TW (1) | TWI253930B (hu) |
| WO (1) | WO2001022956A2 (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0012260D0 (en) * | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| CN100450488C (zh) * | 2003-11-03 | 2009-01-14 | 诺顿·希尔思凯尔有限公司 | 用于干粉吸入剂的软类固醇组合物 |
| EP2221048A1 (en) * | 2009-02-18 | 2010-08-25 | Siegfried Generics International AG | Pharmaceutical composition for inhalation |
| US9238144B2 (en) * | 2013-03-14 | 2016-01-19 | Neuropace, Inc. | Optimizing data retrieval from an active implantable medical device |
| WO2022016150A1 (en) * | 2020-07-17 | 2022-01-20 | Ross Peter M | Methods for the treatment of cytokine release syndromes |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB416950A (en) * | 1933-07-28 | 1934-09-25 | Ambrose Heal | An improved support member for beds, settees, wardrobes and other articles of furniture |
| US4996335A (en) | 1980-07-10 | 1991-02-26 | Nicholas S. Bodor | Soft steroids having anti-inflammatory activity |
| ZA814440B (en) * | 1980-07-10 | 1982-10-27 | Otsuka Pharma Co Ltd | Soft steroids having anti-inflammatory activity |
| US4710495A (en) | 1980-07-10 | 1987-12-01 | Otsuka Pharmaceutical Co., Ltd. | Soft steroids having anti-inflammatory activity |
| TW503113B (en) * | 1997-01-16 | 2002-09-21 | Senju Pharma Co | Aqueous suspension for nasal administration |
| US6461591B1 (en) * | 1997-02-05 | 2002-10-08 | Jago Research Ag | Medical aerosol formulations |
| US5830490A (en) | 1997-04-04 | 1998-11-03 | Weinstein; Robert E. | Method and device for organizing and coordinating the combined use of topical aerosols and oral medications for the treatment of disorders |
| RU2221552C2 (ru) | 1998-11-13 | 2004-01-20 | Джаго Рисерч Аг | Сухой порошок для ингаляции |
-
1999
- 1999-09-30 DE DE19947235A patent/DE19947235A1/de not_active Withdrawn
-
2000
- 2000-09-26 AU AU79074/00A patent/AU7907400A/en not_active Abandoned
- 2000-09-26 ES ES00969304T patent/ES2248131T3/es not_active Expired - Lifetime
- 2000-09-26 US US10/089,449 patent/US7521438B1/en not_active Expired - Fee Related
- 2000-09-26 DK DK00969304T patent/DK1216047T3/da active
- 2000-09-26 BR BRPI0014374-0A patent/BR0014374B1/pt not_active IP Right Cessation
- 2000-09-26 SI SI200030769T patent/SI1216047T1/sl unknown
- 2000-09-26 CA CA002389111A patent/CA2389111C/en not_active Expired - Lifetime
- 2000-09-26 JP JP2001526168A patent/JP5068912B2/ja not_active Expired - Fee Related
- 2000-09-26 HU HU0202753A patent/HUP0202753A3/hu unknown
- 2000-09-26 AT AT00969304T patent/ATE306271T1/de active
- 2000-09-26 MX MXPA02003329A patent/MXPA02003329A/es active IP Right Grant
- 2000-09-26 EP EP00969304A patent/EP1216047B1/de not_active Expired - Lifetime
- 2000-09-26 EE EEP200200163A patent/EE05050B1/xx not_active IP Right Cessation
- 2000-09-26 DE DE50011340T patent/DE50011340D1/de not_active Expired - Lifetime
- 2000-09-26 TW TW089119863A patent/TWI253930B/zh not_active IP Right Cessation
- 2000-09-26 PL PL353487A patent/PL196729B1/pl not_active IP Right Cessation
- 2000-09-26 CZ CZ20021095A patent/CZ296396B6/cs not_active IP Right Cessation
- 2000-09-26 WO PCT/EP2000/009392 patent/WO2001022956A2/de not_active Ceased
- 2000-09-29 AR ARP000105167A patent/AR025924A1/es not_active Application Discontinuation
-
2005
- 2005-12-15 CY CY20051101559T patent/CY1105548T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5068912B2 (ja) | 2012-11-07 |
| CZ296396B6 (cs) | 2006-03-15 |
| PL196729B1 (pl) | 2008-01-31 |
| CZ20021095A3 (cs) | 2002-08-14 |
| WO2001022956A3 (de) | 2001-10-11 |
| TWI253930B (en) | 2006-05-01 |
| AR025924A1 (es) | 2002-12-18 |
| JP2003510276A (ja) | 2003-03-18 |
| DE19947235A1 (de) | 2001-04-05 |
| DE50011340D1 (de) | 2006-02-23 |
| EP1216047A2 (de) | 2002-06-26 |
| MXPA02003329A (es) | 2004-09-10 |
| EE05050B1 (et) | 2008-08-15 |
| BR0014374A (pt) | 2002-06-25 |
| EE200200163A (et) | 2003-04-15 |
| DK1216047T3 (da) | 2006-02-13 |
| US7521438B1 (en) | 2009-04-21 |
| SI1216047T1 (sl) | 2006-02-28 |
| ES2248131T3 (es) | 2006-03-16 |
| BR0014374B1 (pt) | 2012-12-25 |
| PL353487A1 (en) | 2003-11-17 |
| EP1216047B1 (de) | 2005-10-12 |
| CY1105548T1 (el) | 2010-07-28 |
| AU7907400A (en) | 2001-04-30 |
| ATE306271T1 (de) | 2005-10-15 |
| CA2389111C (en) | 2009-04-14 |
| HUP0202753A3 (en) | 2004-06-28 |
| WO2001022956A2 (de) | 2001-04-05 |
| CA2389111A1 (en) | 2001-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100234864B1 (ko) | 기도 및 폐질환을 치료하기 위한 모메타손푸로에이트 약제 | |
| RU2199322C2 (ru) | Новое применение будезонида и формотерола | |
| JP5524442B2 (ja) | 呼吸器疾患の治療のための、抗コリン作用薬及びβ−模倣薬の新規併用薬 | |
| CZ291455B6 (cs) | Léčivo pro podání inhalací | |
| JP2002517450A (ja) | 喘息の急性状態の予防または処置のための、ホルモテロールおよびブデソニドを含んでなる組成物の使用 | |
| JP2005539046A (ja) | 特異的な抗コリン作用薬、β−２アゴニスト、および副腎皮質ステロイドを含む、治療薬および組成物 | |
| KR20050104367A (ko) | 타 활성제와 결합하여 장기 효능을 지속하는 베타2-동근으로 구성되는 약물 | |
| JP5492072B2 (ja) | 喘息の増悪の予防および／または治療のためのフォルモテロールおよびジプロピオン酸ベクロメタゾンを含む組成物の使用 | |
| WO2006065722A2 (en) | Compositions and methods for pulmonary conditions | |
| JP2004507494A (ja) | サルメテロールとプロピオン酸フルチカゾンとの合剤の使用 | |
| HUP0202753A2 (hu) | A loteprednol és B2 adrenoreceptor agonisták új kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| AU2003292120A1 (en) | New synergistic combination comprising roflumilast and formoterol | |
| HK1038703A1 (zh) | 糖皮質類固醇在制備治療輕度/早期copd(慢性阻塞性肺病)的藥物中的應用 | |
| US20060199865A1 (en) | Synergistic combination comprising roflumilast and (r,r) - formoterol | |
| US20020198228A1 (en) | Composition and method for the treatment of respiratory desease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Change of name, address |
Owner name: MEDA PHARMA GMBH & CO. KG, DE Free format text: FORMER OWNER(S): VIATRIS GMBH & CO. KG, DE; VIATRIS GMBH & CO. KG, DE |
|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |